Eiger Biopharmaceuticals Inc. (EIGR) Given Consensus Recommendation of “Buy” by Brokerages

Eiger Biopharmaceuticals Inc. (NASDAQ:EIGR) has been given a consensus rating of “Buy” by the nine ratings firms that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation, seven have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $30.86.

EIGR has been the topic of several research reports. Wedbush reissued an “outperform” rating and set a $36.00 price target (down previously from $53.00) on shares of Eiger Biopharmaceuticals in a research report on Thursday, May 17th. BTIG Research increased their price target on shares of Eiger Biopharmaceuticals from $23.00 to $39.00 and gave the stock a “buy” rating in a research report on Thursday, May 17th. ValuEngine cut shares of Eiger Biopharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Thursday, March 1st. Zacks Investment Research raised shares of Eiger Biopharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, March 22nd. Finally, Oppenheimer set a $26.00 target price on shares of Eiger Biopharmaceuticals and gave the company a “buy” rating in a report on Monday, March 12th.

In related news, insider Joanne Quan sold 4,000 shares of the firm’s stock in a transaction that occurred on Monday, April 2nd. The shares were sold at an average price of $10.00, for a total value of $40,000.00. Following the sale, the insider now owns 4,000 shares of the company’s stock, valued at $40,000. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 7.90% of the stock is owned by company insiders.

Large investors have recently modified their holdings of the stock. Prosight Management LP acquired a new stake in Eiger Biopharmaceuticals in the fourth quarter valued at approximately $9,469,000. Knott David M raised its holdings in Eiger Biopharmaceuticals by 181.2% in the first quarter. Knott David M now owns 61,857 shares of the biotechnology company’s stock valued at $609,000 after acquiring an additional 39,857 shares in the last quarter. Armistice Capital LLC acquired a new stake in Eiger Biopharmaceuticals during the fourth quarter worth approximately $5,357,000. Stonepine Capital Management LLC acquired a new stake in Eiger Biopharmaceuticals during the fourth quarter worth approximately $2,093,000. Finally, Unterberg Capital LLC raised its holdings in Eiger Biopharmaceuticals by 60.0% during the first quarter. Unterberg Capital LLC now owns 80,000 shares of the biotechnology company’s stock worth $788,000 after purchasing an additional 30,000 shares in the last quarter. 65.92% of the stock is currently owned by hedge funds and other institutional investors.

Shares of EIGR opened at $12.10 on Friday. The stock has a market cap of $128.59 million, a PE ratio of -2.49 and a beta of 1.81. Eiger Biopharmaceuticals has a 1 year low of $7.11 and a 1 year high of $18.00. The company has a debt-to-equity ratio of 0.81, a quick ratio of 4.51 and a current ratio of 4.51.

Eiger Biopharmaceuticals (NASDAQ:EIGR) last issued its quarterly earnings results on Friday, May 11th. The biotechnology company reported ($0.84) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.96) by $0.12. analysts predict that Eiger Biopharmaceuticals will post -3.06 EPS for the current year.

Eiger Biopharmaceuticals Company Profile

Eiger BioPharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection.

Analyst Recommendations for Eiger Biopharmaceuticals (NASDAQ:EIGR)

Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply